Dosage and protocol evidence
Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.
0.5 mg daily in weeks 1-2, 1 mg in weeks 3-4, 1.5 mg in weeks 5-6 and 2 mg in weeks 7-8
Human publications mainly measure endogenous MOTS-C; they do not validate this exogenous administration schedule. The source describes community research practice.
View sourceEvidence summary
A mitochondrial-derived peptide supported mainly by cell and animal experiments. Human research largely measures endogenous MOTS-C rather than administering it.
Protocol basis
The evidence page separates human observational physiology from exogenous animal dosing. Neither supplies a defensible injected human protocol.
What remains uncertain
Human pharmacokinetics, dose-response, safety, formulation and clinically meaningful outcomes remain unestablished.